Clinical trials
Advanced Renal Cell Carcinoma clinical trials
Below are recruiting advanced renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 390 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07177937RecruitingPhase 1
Study of DXC014 for advanced solid tumors
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06404281RecruitingPhase 1
Modified immune cells for advanced solid tumors
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
ChangzhouAges 18–80 - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT05772208RecruitingPhase 3
New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT03919552RecruitingPhase 3
Chemoradiation with two cisplatin or carboplatin plans for nasopharyngeal cancer
This Phase 3 trial compares two chemotherapy-and-radiation combinations (cisplatin-based vs carboplatin-based) for locally advanced nasopharyngeal cancer that has not spread to distant organs. It may help researchers find which plan works best while balancing safety and effectiveness.
Guangzhou, GuangdongAges 18–64 - NCT06669572RecruitingPhase 2
Lenvatinib and pembrolizumab for advanced anal or rectal cancer
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT07362979RecruitingPhase 2
Toripalimab with chemo for advanced nasopharyngeal cancer
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
Dongguan, GuangdongAges 18–70 - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06069570RecruitingPhase 1
Gamma delta T cells and low dose radiation for advanced lung or bone cancer
This trial tests a new type of immune cell called gamma delta T cells combined with low-dose radiation to treat people with advanced lung cancer or solid tumors that have spread to the bone. It is only for patients who have already tried standard treatments and either didn't get better or couldn't tolerate them.
Tucson, ArizonaAges 18 years+ - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT07364357RecruitingPhase 1
Study of CREPT-618 for advanced liver cancer
This phase 1 trial tests a new drug called CREPT-618 for people with advanced liver cancer that hasn't responded to standard treatments. The drug is designed to target cancer cells with specific markers (CREPT and ASGPR), so only patients whose tumors have these markers can join.
BeijingAges 18–75 - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06037733Recruiting
Focused radiation to main tumor after chemo-immunotherapy for lung cancer
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
Wuhan, HubeiAges 18–75 - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced renal cell carcinoma?
- Yes. Clin2 currently lists 390 recruiting advanced renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.